Overview

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with asthma, those who smoke and healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Acorda Therapeutics
Treatments:
Oxazolidinones
Zolmitriptan